NCT01213017View on ClinicalTrials.gov

The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

January 31, 2011

Study Completion Date

April 30, 2012

Conditions
Rheumatoid Arthritis
Interventions
DRUG

certolizumab pegol

400mg at week 0, 2 and 4, followed by 200 mg every two weeks for 52 weeks

Trial Locations (2)

33180

Arthritis and Rheumatic Disease Specialties, Aventura

73104

Oklahoma Medical Research Foundation, Oklahoma City

Sponsors

Collaborators (1)

UCB Pharma
All Listed Sponsors
collaborator

UCB Pharma

INDUSTRY

lead

Oklahoma Medical Research Foundation

OTHER